• Matthew J Reinhard, Jeremy E Chester, Charity B Breneman, Immanuel B H Samuel, Michelle K Prisco, Terra D Vincent, Peter D Rumm, Shanna R Smith, and John P Barrett.
• Department of Veterans Affairs, War Related Illness and Injury Study Center (WRIISC), Washington, DC 20422 , USA.
• Mil Med. 2023 Mar 20; 188 (3-4): 689696689-696.

IntroductionTo evaluate the associations between neurocognitive and psychiatric health outcomes with mefloquine or any antimalarial exposure.Materials And MethodsMedical records were systematically reviewed to identify veterans that indicated antimalarial medication use. Linear regression was performed to examine associations between mefloquine/antimalarial exposure and health outcomes. The mefloquine-exposed group was further compared with normative populations for the same health outcomes.ResultsIn the adjusted models, no significant differences were noted between the two exposure groups and the unexposed group for any of the health measures (P-value > 0.05). When compared to normative population samples, the mefloquine-exposed group had poorer health and greater neurobehavioral symptom severity or cognitive complaints.ConclusionThis study suggests that mefloquine use by veterans referred for intensive evaluation of their military deployment exposures and health was not associated with increased, long-term, neurocognitive/psychiatric symptoms compared to unexposed veterans.Published by Oxford University Press on behalf of the Association of Military Surgeons of the United States 2022. This work is written by (a) US Government employee(s) and is in the public domain in the US.

17 keywords...

hide…